Combating immunity to AAV

Ensuring as many patients as possible can benefit from gene therapy

The Duchenne Research Fund has awarded a grant to Dr Barry Byrne and Dr Manuela Corti’s team at the University of Florida, whose vital work focuses on overcoming immunological challenges to ensure all boys and young men can benefit from gene therapy treatments for Duchenne muscular dystrophy.

Why is this research needed?

It is extremely positive news for the Duchenne community that there are currently several gene therapy treatments in clinical trial to combat Duchenne. However, around a third of young people already have a pre-existing immunity to the virus that is used to deliver the gene therapy treatment (known as an adeno-associated virus, or AAV). This means that those patients are unable to participate in current gene therapy trials.

In addition, patients who are eligible to receive the gene therapy will develop immunity to the virus after receiving the first dose, so the challenge of immunity must be overcome in order for them to receive any future doses.

What are the aims of the project?

Dr Byrne and Dr Corti’s work involves developing a strategy to allow dosing in cases of pre-immunity, by modifying the immune system. They aim to establish at what threshhold pre-immunity impacts the safety and efficacy of AAV administration, and to develop a protocol to reduce anti-AAV titers in pre-immune individuals with Duchenne.

They believe this work will have a major impact on the application of gene therapy approaches and provide valuable insight into safe and effective AAV-mediated gene therapy for Duchenne muscular dystrophy.

Dr Barry Byrne is the Associate Chair of Pediatrics and Director of the Powell Center for Rare Disease Research and Therapy. Click here to learn more about his work.

Pre-clinical research

£80,000 contribution

Funded in 2019-21

Florida, USA

Latest research news

FDA approves first gene therapy for Duchenne

The FDA has granted accelerated approval for the gene therapy treatment SRP-9001. This is the first time a gene therapy for Duchenne has been approved anywhere in the world …

See the smart suit that is changing children’s lives

On Rare Disease Day, watch Eli Crossley, son of our friend and Duchenne UK co-founder Emily, as he talks about – and demonstrates – the amazing technological developments that are being trialled for children with Duchenne muscular dystrophy. The ‘smart suit’ aims to help children who are losing upper body function in still continuing to use their arms.

Our projects

Learn more about what we fund.

Get involved

Find out how you can help us beat Duchenne.